Lung Cancer — Trials, FDA Actions & Pivotal Research
59 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Lung Cancer.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Lung Cancer trials
Recruiting trials by city
Cities where Lung Cancer trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedLung Cancer: Virtual Navigation System Shows Improved Bronchoscopy Metrics· May 15, 2026
- Results postedNovel Cone-Beam CT Demonstrates Superior Image Quality for Radiotherapy· May 6, 2026
- Results postedLung Cancer: CT-Guided SBRT Workflow Feasibility Demonstrated in Trial· May 1, 2026
- Results postedLung Cancer: BioSpy System Shows High Accuracy in Tissue Differentiation· Apr 21, 2026
- Results postedPembrolizumab with L-NMMA Phase 1b Trial Identifies 20 mg/kg MTD· Apr 9, 2026· drug: Pembrolizumab
- Results postedKeytruda SC Formulation Preferred by Cancer Patients in Preference Study· Apr 8, 2026· drug: Pembrolizumab
- Primary completionOsimertinib Trial for EGFR-mutant NSCLC Reaches Primary Completion· Mar 31, 2026· drug: Osimertinib
- Results postedLung Cancer: MyLungHealth Intervention Increases Screening Eligibility…· Mar 27, 2026
- Results postedLung Cancer Screening: Community Support Program Participants Attend 21…· Mar 24, 2026
- Primary completionPembrolizumab Trial for Metastatic NSCLC Completes Primary Phase· Mar 12, 2026· drug: Pembrolizumab
- Results postedLung Cancer: SDoH Screening and Referral Boosts Screening Uptake· Mar 11, 2026
- Results postedTrial results posted: NCT04222972· Mar 5, 2026· drug: Pembrolizumab
- Results postedNivolumab + ALT-803 Defines Safety in Advanced NSCLC Trial· Feb 17, 2026· drug: Nivolumab
- Results postedPembrolizumab/NT-I7 Combination Shows Dose-Dependent TEAEs in Solid Tumors· Feb 9, 2026· drug: Pembrolizumab
- Results postedLung Cancer Screening Uptake Intervention Trial Results Posted· Feb 3, 2026
- Results postedAtezolizumab Trial for NSCLC with Brain Metastases Terminated Early· Jan 22, 2026· drug: Atezolizumab
- Results postedKanSurvive-ECHO: Mixed Results for Cancer Survivorship Care Metrics· Jan 14, 2026
- Results postedTrial results posted: NCT04765059· Jan 13, 2026· drug: Osimertinib
- Results postedTrial results posted: NCT05054725· Jan 6, 2026· drug: Sotorasib
- Results postedNew Cone-beam CT Scanner for Radiotherapy: Image Quality Results Posted· Jan 6, 2026
- Primary completionLung Cancer Trial for Sublobar Resection Reaches Primary Completion· Jan 1, 2026
- Primary completionNon-small cell lung cancer trial completes Phase 3 primary endpoint· Jan 1, 2026
2025
- Primary completionAtezolizumab Phase 3 Trial for NSCLC Reaches Primary Completion· Dec 30, 2025· drug: Atezolizumab
- Primary completionAtezolizumab Phase 3 NSCLC Trial Completes Primary Data Collection· Dec 30, 2025· drug: Atezolizumab
- Results postedSotorasib Combination Therapy Shows No Objective Response in NSCLC Trial· Dec 16, 2025· drug: Sotorasib
- Primary completionOsimertinib + Savolitinib NSCLC Trial Reaches Primary Completion· Dec 15, 2025· drug: Osimertinib
- Results postedHOPE-Genomics Trial Results Posted for Cancer Patient Education· Dec 11, 2025
- Primary completionLung Cancer: Wedge Resection Trial Completes Primary Phase· Nov 30, 2025
- Results postedLung Cancer: Transbronchial Microwave Ablation Trial Reports Efficacy· Nov 24, 2025
- Results postedLung Cancer Screening Study: Social Media Reaches Over 1 Million Users· Nov 21, 2025
- Results postedPembrolizumab + Chemo Shows Similar PFS to Tobemstomig + Chemo in NSCLC· Nov 19, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Combination Trial for Advanced Solid Tumors Terminated· Nov 17, 2025· drug: Pembrolizumab
- Results postedOsimertinib: Sequential Gefitinib + Blood Test Shows Higher 18-Month PFS in…· Oct 31, 2025· drug: Osimertinib
- Results postedNivolumab Plus Chemotherapy Improves PFS in Stage IV NSCLC Trial· Oct 30, 2025· drug: Nivolumab
- Results postedTrastuzumab Deruxtecan: Phase 2 NSCLC Umbrella Study Results Posted· Oct 27, 2025· drug: Trastuzumab Deruxtecan
- Results postedAtezolizumab + Tiragolumab Shows No Significant Benefit in ES-SCLC· Oct 22, 2025· drug: Atezolizumab
- Results postedOsimertinib Plus Chemo Trial for Uncommon EGFRm NSCLC Shows 75% ORR· Oct 15, 2025· drug: Osimertinib
- Results postedNivolumab Combination Therapy Shows 9.4 Months PFS in Metastatic NSCLC· Oct 14, 2025· drug: Nivolumab
- Results postedPembrolizumab Combination Trial for NSCLC, Mesothelioma Terminated· Oct 2, 2025· drug: Pembrolizumab
- Results postedLung Cancer: ALK Resistance Mechanisms Identified in NSCLC Progression· Oct 2, 2025
- Primary completionLung Cancer: Phase 3 Surgical Comparison Trial Completes Primary Phase· Sep 30, 2025
- Results postedImproving Cancer On-treatment Symptom Management Trial Results Posted· Sep 25, 2025
- Results postedNivolumab/Ipilimumab Phase 1 Trial in HIV-Associated Cancers Shows Tolerability· Sep 23, 2025· drug: Nivolumab
- Results postedLung Cancer: Diagnostic Yield Data Posted for Terminated nCLE Trial· Sep 17, 2025
- Results postedPembrolizumab with SABR Sequencing in mNSCLC: SABR-first shows higher OS· Sep 15, 2025· drug: Pembrolizumab
- Results postedLung Cancer: Community Support Program Improves Screening Attendance· Sep 2, 2025
- Primary completionLung Cancer Palliative Radiotherapy Study Reaches Primary Completion· Aug 31, 2025
- Results postedAtezolizumab + Chemo Improves Response in Prior-Treated NSCLC· Aug 27, 2025· drug: Atezolizumab
- Results postedPembrolizumab/Vibostolimab Coformulation Fails to Improve OS in NSCLC· Aug 26, 2025· drug: Pembrolizumab
- Primary completionLung Cancer: SAF-189s Phase 3 Trial Reaches Primary Completion· Jul 31, 2025
- Results postedMyoStrain® Trial Results Posted: Detecting Cardiotoxicity in Breast Cancer· Jul 29, 2025
- Results postedLung Cancer: EPIONE Device Shows 1.2mm Accuracy in Percutaneous Procedures· Jul 15, 2025
- Results postedLung Cancer Patients Report Positive Perceptions in PROStep Trial· Jul 2, 2025
- Primary completionPembrolizumab Phase 3 Lung Cancer Trial Reaches Primary Completion· Jul 1, 2025· drug: Pembrolizumab
- Results postedCancer Patients' Treatment Priorities Posted for Elderly and Young· Jul 1, 2025
- Primary completionOsimertinib Phase 3 Study for NSCLC Reaches Primary Completion· May 31, 2025· drug: Osimertinib
- Results postedLung Cancer Screening Eligibility Messaging Trial Results Posted· May 31, 2025
- Primary completionPembrolizumab Untreated Lung Cancer Trial Completes Primary Phase· May 30, 2025· drug: Pembrolizumab
- Results postedPembrolizumab + Chemo in EGFR+ NSCLC Shows 46% Response Rate Post-Targeted…· May 30, 2025· drug: Pembrolizumab